


LDN-211904 oxalate

Cat. No.:	HY-107460		
CAS No.:	1198408-78-4		
Molecular Formula:	C ₂₁ H ₂₁ ClN ₄ O ₅		
Molecular Weight:	444.87		
Target:	Ephrin Receptor		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description	LDN-211904 oxalate (compound 32) is a potent and selective EphB3 inhibitor with an IC ₅₀ of 0.079 μM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC ^{[1][2]} .
IC ₅₀ & Target	IC ₅₀ : 0.079 μM (EphB3) ^[1]

REFERENCES

- [1]. Qiao L, et al. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. *Bioorg Med Chem Lett*. 2009 Nov 1;19(21):6122-6.
- [2]. Park SH, et al. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. *Theranostics*. 2019 Apr 12;9(8):2235-2251.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA